Today: 30 April 2026
Browse Category

NASDAQ:ATON 13 January 2026

AlphaTON Capital (ATON) stock rips after-hours on $46 million Nvidia B300 AI deal — what to watch next

AlphaTON Capital (ATON) stock rips after-hours on $46 million Nvidia B300 AI deal — what to watch next

AlphaTON Capital shares soared 186.8% in after-hours trading Monday after it announced a $46 million deal to acquire 576 Nvidia B300 chips for a Swedish data center. The company said delivery is expected in February, with revenue targeted for March. Financing includes $32.7 million in non-recourse debt and $9.3 million in equity installments. Investors are watching for updates on hardware delivery and revenue timing.
13 January 2026

Stock Market Today

  • Opera (OPRA) Stock Valuation Amid Recent Price Volatility
    April 30, 2026, 8:52 AM EDT. Opera (NasdaqGS:OPRA) shares closed at $17.35, down 2.6% in the latest session, but showing a 21.7% gain over 30 days and 86.7% over three years, indicating strong momentum. The company reported $615 million in annual revenue and $108 million in net income. Analysts see Opera as undervalued by about 19.3%, with a fair value estimate of $21.50. Continued growth in internet access and user acquisition supports this view, but competition from major tech browser companies and heavy investments in AI and MiniPay pose risks. The stock's valuation reflects cautious optimism, balancing growth potential against strategic challenges and reliance on key ad partners.

Latest article

QUALCOMM Incorporated (QCOM) Stock Jumps as AI Data-Center Bet Offsets Weak Forecast

QUALCOMM Incorporated (QCOM) Stock Jumps as AI Data-Center Bet Offsets Weak Forecast

30 April 2026
Qualcomm shares rose 10.3% premarket Thursday after CEO Cristiano Amon said the smartphone market had bottomed and highlighted progress in data-center chips. Fiscal Q2 revenue fell 3% to $10.6 billion, with handset revenue down 13% but automotive up 38%. The Q3 forecast missed Wall Street estimates. Qualcomm expects chip sales to Chinese handset makers to recover after Q3.
Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

30 April 2026
Eli Lilly raised its 2026 revenue forecast by $2 billion after first-quarter sales jumped 56% to $19.8 billion, driven by Mounjaro and Zepbound, which brought in $12.8 billion. Adjusted earnings reached $8.55 per share. The company cited strong demand but noted lower realized prices and competition from Novo Nordisk remain risks. Foundayo, Lilly’s new oral GLP-1 pill, launched in April but was not included in the quarter’s results.
Go toTop